Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab
Angelopoulou, M.K.; Pangalis, G.A.; Sachanas, S.; Kokoris, S.I.; Anargyrou, K.; Galani, Z.; Kalpadakis, C.; Vassilakopoulos, T.P.
Leukemia and Lymphoma 49(9): 1817-1820
2008
ISSN/ISBN: 1042-8194
PMID: 18798112
DOI: 10.1080/10428190802163289
Accession: 054807177
PDF emailed within 0-6 h: $19.90
Related References
Thomas, D.A.; O'Brien, S.; Bueso-Ramos, C.; Faderl, S.; Keating, M.J.; Giles, F.J.; Cortes, J.; Kantarjian, H.M. 2003: Rituximab in relapsed or refractory hairy cell leukemia Blood 102(12): 3906-3911Burotto, M.; Stetler-Stevenson, M.; Arons, E.; Zhou, H.; Wilson, W.; Kreitman, R.J. 2013: Bendamustine and rituximab in relapsed and refractory hairy cell leukemia Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 19(22): 6313-6321
Tiacci, E.; De Carolis, L.; Simonetti, E.; Capponi, M.; Ambrosetti, A.; Lucia, E.; Antolino, A.; Pulsoni, A.; Ferrari, S.; Zinzani, P.L.; Ascani, S.; Perriello, V.M.; Rigacci, L.; Gaidano, G.; Della Seta, R.; Frattarelli, N.; Falcucci, P.; Foà, R.; Visani, G.; Zaja, F.; Falini, B. 2021: Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia New England Journal of Medicine 384(19): 1810-1823
Gerrie, A.S.; Zypchen, L.N.; Connors, J.M. 2012: Fludarabine and rituximab for relapsed or refractory hairy cell leukemia Blood 119(9): 1988-1991
Pollio, F.; Pocali, B.; Palmieri, S.; Morabito, P.; Scalia, G.; Del Vecchio, L.; Ferrara, F. 2002: Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient Annals of Hematology 81(12): 736-738
Shikara, M.M.; Ramzan, M.; Chaudhri, F.; Aziz, A.R. 2003: Hairy cell leukemia-variant treated with rituximab in an elderly patient Blood 102(11): 309b
Robak, T.; Janus, A.; Jamroziak, K.; Tiacci, E.; Kreitman, R.J. 2021: Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox Journal of Clinical Medicine 10(13)
Robak, E.; Jesionek-Kupnicka, D.; Iskierka-Jazdzewska, E.; Janus, A.; Robak, T. 2021: Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab Leukemia Research 104: 106571
Perry, A.M.; Matsuda, K.; Wadhwa, V.; Hewitt, D.; Almiski, M.; Johnston, J.B.; Banerji, V. 2017: Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine Blood Advances 1(14): 899-902
Handa, S.; Lee, J.-O.; Derkach, A.; Stone, R.M.; Saven, A.; Altman, J.K.; Grever, M.R.; Rai, K.R.; Shukla, M.; Vemuri, S.; Montoya, S.; Taylor, J.; Abdel-Wahab, O.; Tallman, M.S.; Park, J.H. 2022: Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy Blood 2022
Ansell, S.M.; Ristow, K.M.; Inwards, D.J.; Micallef, I.N.M.; Porrata, L.F.; Habermann, T.M.; Johnston, P.B.; Litzow, M.R. 2016: Rituximab administration as part of initial therapy may be associated with a poorer outcome in young patients subsequently treated with stem cell transplantation for relapsed chemosensitive large B-cell lymphoma Journal of Clinical Oncology 23(16_Suppl): 6665-6665
Kreitman, R.J.; Dearden, C.; Zinzani, P.L.; Delgado, J.; Robak, T.; le Coutre, P.D.; Gjertsen, B.ør.T.; Troussard, X.; Roboz, G.J.; Karlin, L.; Gladstone, D.E.; Kuptsova-Clarkson, N.; Liu, S.; Patel, P.; Rotolo, F.; Mitry, E.; Pastan, I.; Giles, F. 2021: Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial Journal of Hematology and Oncology 14(1): 35
Goldaniga, M.; Guffanti, A.; Gianelli, U.; Magni, M.; Lambertenghi Deliliers, G.; Baldini, L. 2004: Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab Haematologica 89(11): Ecr41
Jehn, U.; Dietzfelbinger, H.; Bartl, R.; Heinemann, V.; Vehling Kaiser, U.; Wolf Hornung, B.; Hill, W. 1998: Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadeoxyadenosine British Journal of Haematology 102(1): 190
Jehn, U.; Bartl, R.; Dietzfelbinger, H.; Vehling-Kaiser, U.; Wolf-Hornung, B.; Hill, W.; Heinemann, V. 1999: Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine Annals of Hematology 78(3): 139-144
Machii, T.; Kitani, T.; Kimura, K.; Maekawa, I.; Matsuzaki, M.; Mikuni, C.; Niikawa, K.; Igarashi, T.; Abe, T.; Miura, Y. 1988: Interferon-alpha therapy for hairy cell leukemia and lymphoproliferative disorders simulating hairy cell leukemia (hairy cell leukemia variant): a cooperative group study in Japan Japanese Journal of Clinical Hematology 29(11): 2029-2036
Igarashi, T.; Kobayashi, Y.; Ogura, M.; Kinoshita, T.; Ohtsu, T.; Sasaki, Y.; Morishima, Y.; Murate, T.; Kasai, M.; Uike, N.; Taniwaki, M.; Kano, Y.; Ohnishi, K.; Matsuno, Y.; Nakamura, S.; Mori, S.; Ohashi, Y.; Tobinai, K. 2002: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase Ii study Annals of Oncology: Official Journal of the European Society for Medical Oncology 13(6): 928-943
Ribeiro, P.; Bouaffia, F.; Peaud, P.Y.; Blanc, M.; Salles, B.; Salles, G.; Coiffier, B. 1999: Long term outcome of patients with hairy cell leukemia treated with pentostatin Cancer 85(1): 65-71
Jacobs, A.D.; Naiem, F.; Champlin, R.E.; Golde, D.W. 1985: Toxicity and bone marrow response of patients with hairy cell leukemia treated with biosynthetic (recombinant) -2-interferon Annals of Hematology 50(1): 33-34
Panovská, A.; Smolej, L.áš; Lysák, D.; Brychtová, Y.; Šimkovič, M.; Motyčková, M.; Vodárek, P.; Lindtnerová, M.; Trbušek, M.; Malčíková, J.; Pospíšilová, Šár.; Mayer, J.ří; Doubek, M. 2013: The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab European Journal of Haematology 90(6): 479-485